A phase I report describes durable peritoneal disease control in three advanced gastric cancer patients with peritoneal metastases treated with satri-cel, a claudin 18.2-targeted CAR-T therapy. All three patients had high CLDN18.2 expression and showed clinical and radiologic benefit, including one case enabling conversion surgery. The peritoneal space is typically difficult to treat with systemic therapies due to limited drug penetration and unique immune dynamics. The reported post-infusion kinetics—rapid decline in circulating CAR-T with sustained local control—suggest that tumor-site persistence may drive outcomes. While the cohort size is small, the case series directly addresses an evidence gap for peritoneal metastatic gastric cancer and provides rationale for deeper phase testing with safety and efficacy endpoints focused on peritoneal lesions.
Get the Daily Brief